These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 22290239

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
    Chege D, Kovacs C, la Porte C, Ostrowski M, Raboud J, Su D, Kandel G, Brunetta J, Kim CJ, Sheth PM, Kaul R, Loutfy MR.
    AIDS; 2012 Jan 14; 26(2):167-74. PubMed ID: 22089379
    [Abstract] [Full Text] [Related]

  • 3. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.
    Vallejo A, Gutierrez C, Hernandez-Novoa B, Diaz L, Madrid N, Abad-Fernandez M, Dronda F, Perez-Elias MJ, Zamora J, Muñoz E, Muñoz-Fernandez MA, Moreno S.
    AIDS; 2012 Sep 24; 26(15):1885-94. PubMed ID: 22992577
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.
    Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.
    Scand J Immunol; 2008 Dec 24; 68(6):652-60. PubMed ID: 19055701
    [Abstract] [Full Text] [Related]

  • 7. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
    Puertas MC, Massanella M, Llibre JM, Ballestero M, Buzon MJ, Ouchi D, Esteve A, Boix J, Manzardo C, Miró JM, Gatell JM, Clotet B, Blanco J, Martinez-Picado J, MaraviBoost Collaborative Group.
    AIDS; 2014 Jan 28; 28(3):325-34. PubMed ID: 24185044
    [Abstract] [Full Text] [Related]

  • 8. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S, AIEDRP Network.
    J Infect Dis; 2006 Sep 15; 194(6):725-33. PubMed ID: 16941337
    [Abstract] [Full Text] [Related]

  • 9. Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+ T-cell activation.
    Kolber MA, Saenz MO, Tanner TJ, Arheart KL, Pahwa S, Liu H.
    Clin Immunol; 2008 Mar 15; 126(3):315-21. PubMed ID: 17997138
    [Abstract] [Full Text] [Related]

  • 10. Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification.
    Massanella M, Esteve A, Buzón MJ, Llibre JM, Puertas MC, Gatell JM, Domingo P, Stevenson M, Clotet B, Martinez-Picado J, Blanco J, IntegRal Collaborative Group.
    J Acquir Immune Defic Syndr; 2013 Jun 01; 63(2):152-60. PubMed ID: 23392458
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
    Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B, Palmer S, Medvik K, Lederman MM, Alatrakchi N, Jacobson JM, Wiegand A, Kearney M, Coffin JM, Mellors JW, Eron JJ, AIDS Clinical Trials Group A5244 team.
    PLoS Med; 2010 Aug 10; 7(8):. PubMed ID: 20711481
    [Abstract] [Full Text] [Related]

  • 15. Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir.
    Koelsch KK, Boesecke C, McBride K, Gelgor L, Fahey P, Natarajan V, Baker D, Bloch M, Murray JM, Zaunders J, Emery S, Cooper DA, Kelleher AD, PINT study team.
    AIDS; 2011 Nov 13; 25(17):2069-78. PubMed ID: 21860347
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A, Delfraissy JF, Venet A, Meyer L, Sinet M, ANRS CO6 PRIMO Study Group.
    Antivir Ther; 2012 Nov 13; 17(6):1001-9. PubMed ID: 22865544
    [Abstract] [Full Text] [Related]

  • 20. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
    Canducci F, Barda B, Ceresola E, Spagnuolo V, Sampaolo M, Boeri E, Nozza S, Cossarin F, Galli A, Gianotti N, Castagna A, Lazzarin A, Clementi M.
    Clin Microbiol Infect; 2011 Jun 13; 17(6):928-34. PubMed ID: 20854427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.